Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen.
Strydom N, Ernest JP, Imperial M, Solans BP, Wang Q, Tasneen R, Tyagi S, Soni H, Garcia A, Bigelow K, Gengenbacher M, Zimmerman M, Xie M, Sarathy JP, Yang TJ, Dartois V, Nuermberger EL, Savic RM.
Strydom N, et al. Among authors: tasneen r.
Nat Commun. 2024 Aug 25;15(1):7311. doi: 10.1038/s41467-024-50781-4.
Nat Commun. 2024.
PMID: 39181887
Free PMC article.
Clinical Trial.